• The study by Lo http www apexbt com media

  2024-05-07

  

  The study by Lowry et al. (2001) pointed toward functionally uncharacterized DA- and 5-HT-accumulating neurons within the DMH as a potential target for rapid nongenomic effects of CORT. Similar DA- and 5-HT-accumulating systems are distributed throughout the central and peripheral nervous systems, s

• The biology of the A BR is

  2024-05-07

  

  The biology of the A2BR is complex and needs to be considered contextually as the expression and effect of receptor engagement varies according to time post hypoxic injury, cell type and downstream signaling pathway. For example, A2BR expression is dynamic - low under basal and increasing under isch

• GMF was later localized to the cytosol of primary astrocytes

  2024-05-07

  

  GMFβ was later localized to the cytosol of primary astrocytes and glioma cell lines [67], prompting investigations into its involvement in intracellular signaling. It was found that PKA phosphorylation of GMFβ inhibits the ERK1/2 branch of the MAP kinase pathway [73], yet activates the stress-respon

• Introduction The lysosomal storage disorder

  2024-05-07

  

  Introduction The lysosomal storage disorder Gaucher disease (Mendelian Inheritance in Man, OMIM #230800) results from the recessively inherited deficiency of lysosomal glucocerebrosidase (GCase, EC 3.2.1.45), caused by mutations in the gene GBA1 (MIM# 606463) located on chromosome 1q21. The enzymat

• The obtained results indicate that

  2024-05-06

  

  The obtained results indicate that even when the impairment of the same forms of memory are present, amnesia can develop in different ways. Impairment of memory reconsolidation in the conditioned food aversion model through both the serotonin receptor antagonist and the antagonist of NMDA glutamate

• Aurora A or B selective and pan aurora

  2024-05-06

  

  Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas

• br Introduction Cadmium is a

  2024-05-06

  

  Introduction Cadmium is a major component of heavy metal pollution. Phytoremediation is considered to be the more effective method for recovering contaminated soil [[1], [2], [3], [4]] via cadmium absorption, transport, and accumulation. Several cadmium-associated proteins have previously been we

• Exposure to cisplatin with ATR inhibitor resulted in an incr

  2024-05-06

  

  Exposure to cisplatin with ATR inhibitor resulted in an increase in cisplatin-DNA adducts, especially in cells with ATM deficiency. This finding indicates that suppressing ATR-Chk1 signaling with VE-822 enhances cisplatin activity by enabling the drug to form DNA adducts. Therefore, VE-822 may incre

• A high throughput screening campaign

  2024-05-06

  

  A high-throughput screening campaign led to the discovery of the first series of both potent and selective ATR kinase inhibitors by Vertex Pharmaceuticals (Charrier et al., 2011). One of these compounds, VE-821, was shown to be a potent ATP-competitive inhibitor of ATR with minimal cross-reactivity

• The distribution and subcellular localization differs betwee

  2024-05-06

  

  The distribution and subcellular localization differs between the subtypes of mGlu receptors. Most mGlu receptors are broadly expressed in the brain, except for mGlu6, which is restricted to the retina. Some mGlu receptors are additionally found in glial cells, such as mGlu3 and mGlu5 (Aronica et al

• Findings of the present study provide a molecular mechanism

  2024-05-06

  

  Findings of the present study provide a molecular mechanism for the elevated ASK1 expression in obesity and how it may be functionally linked to whole-body insulin resistance. The role our findings assign to increased E2F1 in upregulating ASK1 parallels the capacity of this transcription factor to r

• A phase I trial has recently

  2024-05-06

  

  A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with

• In conclusion we demonstrated that in

  2024-05-06

  

  In conclusion, we demonstrated that, in the skeletal muscle of rats with T1DM, CRBN levels increased and AMPK, Akt, GLUT4, PGC-1α, and FNDC5 levels decreased, resulting in increased fasting glucose levels. Aerobic exercise training decreased levels of CRBN, which was possibly mediated by AMPK, Akt,

• PF is orally bioavailable and has appropriate pharmacokineti

  2024-05-06

  

  PF-06409577 is orally bioavailable and has appropriate pharmacokinetic properties for use in rodents, allowing us to evaluate its impact on lipid and cholesterol biosynthesis in vivo (Cameron et al., 2016). PF-06409577 lowered the incorporation of 14C-acetate into hepatic lipids in vivo in a dose de

• P005091 australia The evidence points toward a role for

  2024-05-06

  

  The evidence points toward a role for 12/15-LO activity in WAT in modulating chronic local inflammation and subsequent systemic metabolic decline in the obese state. However, little is known as to the role of 12- and 15-LOs in BAT. Indeed, in addition to WAT, platelet- and leukocyte-type 12-LO are e

14368 records 113/958 page Previous Next First page 上5页 111112113114115 下5页 Last page